---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021767"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:55:49.229489+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE

## Summary
- Merger with United Dogecoin closed May 6; Shuttle issued 8,403 Series B-1 Preferred shares convertible at $1.24.
- Closed $9.55M PIPE financing with Series B-2 Preferred and Common Warrants, convertible at $1.03.
- Appointed Ryan Trasolini (ex-United Dogecoin CEO) as Co-Chief Executive Officer effective at closing.
- Amended Asset Purchase Agreement: paid $3.65M cash, issued 270 Series B-1 shares; seller returned 320,496 common shares.
- Director Oleh Nabyt resigned May 3 with no disagreement with management or board.

## SEC filing metadata
- accession: 0001493152-26-021767
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021767
- JSON: https://secwatch.observer/filing/0001493152-26-021767.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021767.txt

## Source-grounded claims
- claim_id: df10913037
  claim: Ryan Trasolini was appointed as Co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm
- claim_id: e07779bd5c
  claim: Oleh Nabyt resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: On May 3, 2026 (the “ Termination Date ”), independent director Oleh Nabyt resigned from the Board of Directors of Shuttle, effective as of the Termination Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm
- claim_id: 3cc6d3ab9a292b16a9e265fd6d9bec854fa50872
  claim: Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving United Dogecoin Inc. (closed 2026-05-06).
  evidence_excerpt: On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm
- claim_id: 302ffb256875cbe407ac5364668adda57b037e88
  claim: Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Agreement and Plan of Merger entered into on April 30, 2026 by and among Acquiror, Merger Sub and th (effective 2026-04-30).
  evidence_excerpt: On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm
- claim_id: ba6163b00aa592784f0a44f5dbffaa394967a34a
  claim: Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Securities Purchase Agreement for issuance of Series B-2 convertible preferred stock and common stoc (effective 2026-04-30).
  evidence_excerpt: on April 30, 2026, the Acquiror entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors party thereto (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Acquiror agreed to issue (i) 1,910 newly designated Series B-2 convertible preferred stock, par value $0.00001 (the “ Series B-2 Preferred Stock ”) and (ii) common stock purchase warrants (the “ Common Warrants ” and together with the Series B-2 Preferred Stock, the “ PIPE Securities ”) to purchase up to 100% of the number of shares of Common Stock underlying the Series B-2 Convertible Preferred Stock as of the Closing Date, exercisable for a period of three (3) years at an exercise price of $1.03 per share (the “ PIPE Financing ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315226021767/0001493152-26-021767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.